Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome

Myelodysplastic syndrome (MDS) is a hematological malignancy of undetermined etiology, possibly linked to chromosomal structural alterations, genetic mutations, presentation and carcinogenicity variant antigens on cell surface, the generation pro-inflammatory microenvironment in bone marrow. Current drugs are unable cure this disease, therefore, decreasing survival proliferation malignant cells delay disease progression extend time patients becomes primary approach management. In recent years, immune system has received increasing attention for its potential role occurrence development MDS, leading emergence immunoregulation as viable treatment option. The current review provides brief overview pathogenesis MDS principles. meantime, significance proteins prognosis also discussed.